BioTech PR is the practice of building media presence, scientific credibility, and market visibility for biotechnology companies. It covers clinical trial announcements, funding rounds, regulatory milestones, thought leadership, and AI discoverability. In a sector where investor trust and scientific credibility are everything, PR helps your company earn the attention of investors, healthcare partners, and journalists before your competitors define your story. The goal is not just coverage. It is commercial impact.
BioTech investors and healthcare partners research extensively before committing, and they look for companies with visible, credible scientific voices. PR builds that presence continuously, not just around clinical readouts or funding announcements. For startups, it establishes early credibility with investors and strategic partners. For scaleups, it supports market expansion, commercial partnerships, and pre-IPO visibility. Without consistent PR, BioTech companies risk being invisible when investors and partners are actively evaluating the space.
BioTech PR in Europe requires local media relationships and an understanding of regional regulatory frameworks like EMA guidelines and EU clinical trial regulations, which are major drivers of investment and partnership decisions across the continent. The European market spans distinct media environments, from the Nordics and DACH to Benelux and Southern Europe. PRLab operates across Amsterdam, Stockholm, Munich, and Madrid, giving BioTech companies genuine local presence and the scientific context that resonates with European investors and healthcare partners.
BioTech PR in the US is built around earning coverage in the publications that investors, healthcare partners, and scientific communities actually read, from the Financial Times and Forbes to Reuters and vertical trade media covering drug discovery and medical devices. The US is the world's largest BioTech market and competition for investor and journalist attention is intense. Breaking through requires credible science, strong executive voices, and stories that connect clinical progress to real commercial potential. PRLab runs US BioTech PR from its Austin office with dedicated local media relationships.
A funding announcement is one of the highest-impact PR moments a BioTech company has. Done well, it generates coverage across science, business, and healthcare media simultaneously, signaling clinical progress and investment readiness to partners and future investors. PRLab has managed funding announcements for BioTech companies at every stage, from seed rounds to Series A and beyond, securing coverage in publications including the Financial Times, TechCrunch, Reuters, and Business Insider.
AI discoverability, also called GEO or AEO, is the practice of ensuring your brand appears accurately and prominently when AI tools like ChatGPT, Claude, or Gemini are queried about your category, therapeutic area, or technology. Investors, healthcare partners, and scientific collaborators increasingly use AI tools to research companies before engaging. A BioTech company that is not visible in those results is losing consideration before the conversation even starts. PRLab builds AI discoverability into every BioTech PR program.
